血栓友好症,低纤维素溶解和骨 necrosis 的情况
1Cholesterol, Metabolism, and Thrombosis Research Center, Middleton Ave, 3906, Cincinnati, OH, USA. sonar16@gmail.com.
Orthopadie (Heidelberg, Germany)
|February 19, 2025
概括
抗凝固疗法可以预防原发性骨 necrosis (ON) 与血栓友-hypofibrinolysis的关节崩,但对二次ON或后崩无效. 早期干预对于像珀斯病和后COVID ON.这样的疾病至关重要.
科学领域:
- 整形外科 整形外科 整形外科
- 血液学 血液学 血液学
- 血管医学 血管医学
背景情况:
- 骨髓缩 (ON) 可能导致关节崩,需要关节置换.
- 亲属血栓友爱-低纤维素溶解是ON的危险因素.
- 主要ON,特别是与血栓友-低纤维素解析,呈现出一个独特的临床场景.
研究的目的:
- 为了评估抗凝剂在治疗与血栓友-低纤维素溶解相关的原发性骨 necrosis (ON) 的疗效.
- 为了确定最佳的时间和患者群体对抗凝血在ON.
- 探索抗凝剂在特定ON环境中的作用,包括珀斯病和COVID后ON.
主要方法:
- 对原发性和二次性ON患者病例的回顾性分析.
- 基于抗凝血开始时间的治疗结果的审查.
- 血栓友好症-低纤维素溶解状态与治疗反应的相关性.
主要成果:
- 在关节崩之前的抗凝剂有效地预防疼痛,关节衰竭,以及在初级ON中需要用血栓友好-低纤维素溶解替换关节的需要.
- 在二次ON中或在关节崩后启动时,抗凝药是不成功的.
- 抗凝药可能对珀斯病和COVID后急性ON有好处,特别是在V因子Leiden突变的情况下.
结论:
- 在关节崩之前,抗凝药应被视为家族血栓性-低纤维素解析患者的ON的主要治疗方式.
- 及时的抗凝剂对于在特定的ON呈现中取得有利结果至关重要.
- 对于二次性ON和其他特定病因的抗凝固作用,需要进一步的研究.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
597
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
597
01:24Disorders of Hemostasis
686
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
686
01:16Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
4.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.9K
01:09Coagulation
4.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.3K